We receive funding from a variety of sources that recognize the value of our high-impact research.
Richard Browne, PhD
Contract Renewal: Clinical Pharmacology Quality Assurance and Quality Control. Richard Browne (Co-Investigator), Gene Morse (Principal Investigator). NIH/National Institute of Allergy and Infectious Disease. $12,754,564. 3/1/2015-2/1/2022.
The metabolomics of neurofilaments, neurodegeneration nexus in Multiple Sclerosis progression. Richard Browne (Co-Investigator). DOD. 7/1/2020-6/1/2023.
Effect of Complex Mixtures of Oxidative Stress and Cognition in Children. Richard Browne (Co-Investigator). NIH/NIEHS. 9/1/2020-6/1/2025.
The Metagenomics Education Partnership: Harnessing the Power of Microbial Genome Sequencing and Big Data with High School Students and Teachers. Stephen Koury (Co-Principal Investigator). NIH. $1,324,101. 6/1/2020-5/1/2025.
Mapping Heterogeneous Dopamine Signaling in Subregions of the Olfactory Tubercle and Its Effect on Psychostimulant-induced Behaviors. Jinwoo Park (Principal Investigator). NIH/NIDA. $408,034. 7/1/2018-6/1/2022.
Noradrenergic Modulation of Dopaminergic Neuronal Functions. Jinwoo Park (Principal Investigator). Whitehall Foundation. $225,000. 9/1/2017-8/1/2022.
Effects of mesolimbic amylin signaling on macronutrient intake. Jinwoo Park (Co-Investigator). NIH/NIDDK. $2,202,189. 12/1/2021-11/1/2026.
Selective galactosylceramidase ablation to study the pathogenesis of Krabbe leukodystrophy. Daesung Shin (Principal Investigator). NIH-NINDS. $1,395,624. 12/1/2019-11/1/2023.
The peripheral nervous system: A window into Krabbe disease. Daesung Shin (Co-Investigator). NIH-NINDS. $2,129,163. 2/1/2019-1/1/2024.
